Kura Oncology, INC

Kura Oncology announced robust second quarter 2026 financial results, highlighted by significant revenue growth for KOMZIFTI and promising clinical updates for its pipeline assets.

Kura Oncology has amended executive employment agreements, modifying severance provisions for key officers in the event of termination or corporate transactions.

Kura Oncology announced its fourth quarter and full year 2025 financial results, highlighting the successful early commercial launch of KOMZIFTI and significant progress in its AML and solid tumor pipelines.

Kura Oncology, Inc. has adopted amended and restated bylaws, effective January 28, 2026, introducing significant changes to corporate governance, stockholder meeting procedures, and director indemnification.

Kura Oncology announced preliminary KOMZIFTI revenue of $2.1 million for its initial commercial period and detailed key development milestones for 2026.

Kura Oncology announced the first U.S. commercial sale of KOMZIFTI, triggering a $135 million milestone payment from Kyowa Kirin.

Kura Oncology announces Q2 2026 results, showing $9.1M in KOMZIFTI net product revenue, but also a net loss of $68.3M.

Kura Oncology announces first quarter 2026 results, with $5.8 million in KOMZIFTI net product revenue and continued investment in pipeline development.

Kura Oncology reports significant clinical progress for its lead cancer therapies, ziftomenib, darlifarnib, and tipifarnib, alongside increased collaboration revenue, despite widening net losses in Q3 2025.

Kura Oncology reports Q2 2025 financial results, highlighting significant progress in its ziftomenib program with FDA Priority Review and positive clinical data, alongside continued operating losses.

Kura Oncology's Q1 2025 results highlight a net loss but significant collaboration revenue from the Kyowa Kirin agreement and progress in clinical trials.

Kura Oncology's Q3 2024 report highlights ongoing clinical trials and financial stability with $455.3 million in cash, cash equivalents, and short-term investments.

Kura Oncology achieved a pivotal milestone with FDA approval and commercial launch of KOMZIFTI for relapsed or refractory NPM1-mutated AML, while advancing a diversified oncology pipeline.

Kura Oncology partners with Kyowa Kirin in a global collaboration for ziftomenib, while also reporting positive topline results from its Phase 2 KOMET-001 trial.

Kura Oncology's 2023 10-K filing details the company's financial status, clinical trial progress, and strategic direction, highlighting advancements in its precision medicine pipeline.

Troy Edward Wilson, President and CEO and a Director of Kura Oncology, Inc., purchased 100,000 shares of common stock on August 17, 2026 for $11.12 per share.

Director Diane Parks was granted 35,000 stock options in Kura Oncology, Inc. with an exercise price of $8.77.

Director Michael Vasconcelles was granted 35,000 stock options in Kura Oncology, Inc. as part of a standard equity compensation arrangement.

Director Faheem Hasnain was granted an option to purchase 35,000 shares of Kura Oncology common stock.

Director Helen Collins was granted an option to purchase 35,000 shares of Kura Oncology common stock at an exercise price of $8.77.

Director Carol Schafer was granted 35,000 stock options in Kura Oncology, Inc. as part of a standard equity compensation package.

Kura Oncology, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, to elect directors, ratify auditor appointments, and vote on equity plan amendments.

Kura Oncology will hold its annual stockholders meeting on June 5, 2025, seeking votes on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Kura Oncology is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of Ernst & Young LLP, approve executive compensation, and amend the 2014 Equity Incentive Plan.

Kura Oncology will hold its annual stockholders meeting on June 5, 2024, to vote on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Kura Oncology is holding its 2024 Annual Meeting of Stockholders on June 5, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.

Montanova Capital, Averill Master Fund, and Aaron Cowen have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Kura Oncology, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,736,000 shares, representing 4.23% of Kura Oncology, Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has disclosed beneficial ownership of over 4.4 million shares, representing 5.01% of Kura Oncology Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Kura Oncology Inc. following an internal realignment.

State Street Corporation has reported a 5.7% beneficial ownership stake in Kura Oncology Inc. common stock as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5.37% in Kura Oncology, Inc., holding 4,672,000 shares as of September 30, 2025.